Product Details
| Product Name:
JI6 |
CAS No.:
856436-16-3 |
| Purity:
98.64% |
Supply Ability:
10g |
| Release date:
2025/12/04 |
Product Introduction
Bioactivity
| Name | JI6 |
| Description | JI6 (JAK3 Inhibitor VI) is a potent, selective and orally active FLT3 inhibitor. JI6 exhibits IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits c-Kit and JAK3, with IC50s of ∼500 and ∼250 nM, respectively. JI6 has research value in acute myeloid leukemia. |
| In vitro | JI6 (3-1000 nM; 1-4 days) inhibits MV4-11 cell viability dose-dependently with an IC50 of ∼25 nM. It also potently inhibits the viability of HCD-57 cells expressing FLT3-ITD, FLT3-D835Y, and FLT3-D835H (1-2000 nM; 48 h) with an IC50 of ∼40 nM, while showing no effect on parent HCD-57 or JAK2V617F expressing cells. Additionally, JI6 (100-500 nM; 24 h) induces apoptosis and cell cycle arrest, and (50-500 nM; 3 h) inhibits phosphorylation of FLT3, ERK, and Akt in HCD-57 cells expressing FLT3-ITD and FLT3-D835Y[1]. |
| In vivo | JI6 (15 mg/kg; i.p. daily for 3 weeks) inhibits the proliferation of HCD-57 expressing FLT3-D835Y in SCID mice and prolongs survival. JI6 (25 mg/kg; p.o. daily for 3 weeks) inhibits the myeloproliferative phenotype in FLT3-ITD knock-in mice. JI6 (100 mg/kg; a single i.p.) significantly inhibits FLT3 phosphorylation and downstream signal transduction in mice expressing FLT3-D835Y[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.5 mg/mL (11.74 mM), Sonication is recommended.
|
| Keywords | JI-6 | JI6 | JI 6 | FLT3 |
| Inhibitors Related | Gilteritinib | Regorafenib monohydrate | Sunitinib | Ruxolitinib | Sorafenib | Tofacitinib Citrate | Dasatinib | Regorafenib | Lenvatinib mesylate | Lenvatinib | Pazopanib | Lentinan |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Hematonosis Compound Library | JAK-STAT Compound Library | Angiogenesis related Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:932359-76-7
$329.00 / 1mg
-
CAS:2160546-07-4
$96.00 / 1mg
-
CAS:851599-82-1
$165.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States